Business Context and Reporting Period
Company: Cyclacel Pharmaceuticals, Inc. (Note: Input metadata referenced "Bio Green Med Solution, Inc.", but the filing text identifies the registrant as Cyclacel Pharmaceuticals, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: June 20, 2025
Event: Entry into a Material Definitive Agreement for a private placement of equity securities.
Key Financial Metrics and Transaction Details
This filing reports a capital raise rather than periodic financial performance metrics (revenue, profit, cash flow). Key transaction figures include:
- Gross Proceeds: $3,000,000
- Securities Issued: 3,000,000 shares of Series F Convertible Preferred Stock
- Purchase Price: $1.00 per share of Series F Preferred Stock
- Warrants Issued: 29,430,000 total common stock purchase warrants (Series A, B, and C)
- Use of Proceeds: General corporate and operating purposes
Material Changes and Transaction Terms
The Company entered into a Securities Purchase Agreement with accredited investors. Material terms include:
- Conversion Rights: Each share of Series F Preferred Stock converts into 3.27 shares of Common Stock.
- Ownership Limitation: Conversion is capped so no investor holds more than the lower of (i) the maximum percentage allowed under Nasdaq rules without a stockholder vote, or (ii) 4.99% of outstanding Common Stock prior to issuance.
- Warrant Terms:
- Series A: 3,270,000 shares per investor at $0.51 exercise price.
- Series B: 3,270,000 shares per investor at $0.60 exercise price.
- Series C: 3,270,000 shares per investor at $0.68 exercise price.
- Expiration: All warrants expire five years from issuance.
- Liquidation Preference: Holders receive $1.00 per share plus accrued dividends prior to Common Stock holders.
- Voting Rights: Series F Preferred Stock votes on an as-converted basis with Common Stock.
Guidance, Outlook, and Risks
Management Commentary: The Company intends to use proceeds for general corporate purposes. Stockholder approval is required for the issuance of Common Stock upon conversion of the Preferred Stock and exercise of Warrants to comply with Nasdaq rules.
Risks and Contingencies:
- Stockholder Approval: The transaction is contingent on obtaining stockholder approval for the issuance of shares upon conversion/exercise.
- Forward-Looking Statements: Actual results may differ due to risks detailed in the Company's Form 10-K (year ended Dec 31, 2024) and Form 10-Q (quarter ended March 31, 2025).
- Regulatory Exemption: Securities were sold unregistered under Regulation S (outside the U.S. to non-U.S. persons).
Investor Verification Checklist
- Verify the total number of outstanding Common Stock shares to calculate the potential dilution impact of the 3.27 conversion ratio and 29,430,000 warrants.
- Confirm the status of the required stockholder vote for the issuance of shares upon conversion and warrant exercise.
- Review the full text of the Series F Certificate of Designations (Exhibit 3.1) for specific dividend and liquidation terms.
- Check the Company's most recent Form 10-K and 10-Q for current liquidity position and cash burn rate to assess the impact of the $3 million raise.
- Confirm the identity of the accredited investors and any related party transactions not explicitly detailed in the summary.